| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Interim Results of HGP-30 AIDS Vaccine Study ALEXANDRIA, Va., Oct. 30, 1996 -- In response to multiple investor inquiries, CEL-SCI CORPORATION (Nasdaq: CELI) announces interim results of its Phase I safety study with the HGP-30 AIDS vaccine in HIV infected individuals. AIDS ReSearch Alliance, a non-profit AIDS research organization located in West Hollywood, California, is conducting the 24 patient study. The interim analysis at week 10 shows the first two administrations of the HGP-30 AIDS vaccine to be safe in HIV infected patients. Proof of safety of HGP-30 in HIV infected individuals is the primary goal this study was designed to achieve. Further, when evaluated as a group, disease stabilization during the 10 week evaluation period was seen in patients with a CD4 count between 300 and 750. The number of patients with a CD4 count between 50 and 300 is too small to make a generalized statement. The study is expected to be completed by the Summer of 1997. Based on these interim results, CEL-SCI Corporation is currently preparing for additional HGP-30 studies in Thailand. Those tests are expected to start in the second half of 1997. Additional studies in the U.S. are also under investigation. At the International Conference on AIDS this past Summer, Dr. James Kahn of San Francisco General Hospital reported protection against HIV infection using the blood of five HGP-30 vaccinated, non-infected volunteers in SCID mice. This is the first time that protection by an AIDS vaccine has been demonstrated with a HIV challenge model. CEL-SCI Corporation is a pioneer in the field of natural immunotherapy. The Company is developing immune based treatments for cancer, AIDS and tuberculosis. Recently, CEL-SCI Corporation signed a collaborative agreement with the U.S. Navy to jointly develop a malaria vaccine and a collaboration agreement with Northeastern Ohio University College of Medicine to jointly develop a herpes vaccine.
|